2[1]Latchhman DS. Transcription factor mutations and disease [J]. N Engl J Med, 1996, 334:28～33.
3[2]Sullenger BA, Gallardo HF, Ungers GE, et al. Overexpression of TAR sequence renders cells resistant to human immunodeficiency virus replication [J]. Cell, 1990, 63:601～608.
4[3]Bahner I, Kearns K, Hao QL, et al. Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus bype 1 replication in myelomonocytic cells produced in iong-term culture [J]. J Virol, 1996, 70: 4352～4360.
5[4]Lee SW, Gallardo HF, Gaspar O, et al. Inhibition of HIV-1 in CEM cells by a potent TAR decoy [J]. Gene Ther, 1995, 2:377～384.
6[5]Tanaka H, Vickart P, Bertrand JR, et al. Sequence-specific interaction of alpha-beta-anomeric double-stranded DNA with the p50 subunit of NF kappa B: application to the decoy approach [J]. Nucleic Acids Res, 1994, 22(15): 3069～74.
7[6]Michael J M, Victor D. Therapeutic applicaton of transcription factor decoy oligonucleotides [J]. Journal of Clin Invest, 2000, 106(9):1072～1075.
8[7]Mann MJ, Whittemore AD, Donaldson MC, et al. Preliminary clinical experience with genetic engineering of human vein grafts:evidence for target gene inhibition [abstract][J]. Circulation, 1997, 96(suppl 1): 1.～4.
9[8]Morishita R, Gibbons GH, Horiuchi M, et al. A novel molecular strategy using cis element "decoy" of E2F binding site inhibits smooth muscle proliferating in vivo [J]. Proc Natl Acad Sci USA, 1995, 92: 5855～5859.
10[9]Libby P, Schwartz D, Brogi E, et al. A cascade model for restenosis: a special case of atherosclerosis progression [J]. Circulation,1992, 86(suppl 3): 3-47.
